Please assess the completion status of the following clinical trial:

Trial Title: A Study LY2228820 for Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer~* Have been treated one time with a platinum-based chemotherapy and your disease has come back at least six months after you completed treatment~* Are able to swallow tablets~* Have given written informed consent prior to any study procedures~* Have adequate blood counts, hepatic and renal function~* Have performance status equal to or less than 2 on Eastern Cooperative Oncology Group (ECOG) scale~* Have negative pregnancy test, and if participant is of child bearing potential must use birth control while on study and for three months after stopping study drug~Exclusion Criteria:~* Have been previously treated with Gemcitabine for ovarian, fallopian tube or primary peritoneal cancer~* Are currently enrolled or discontinued less than 14 days from another clinical trial~* Have a history of inflammatory bowel disease (Crohn's disease or ulcerative colitis)~* Have taken certain medications or had grapefruit juice within 7 days of initial dose of study drug, as levels of the study drug may be affected.~* Must not be pregnant or breastfeeding.~* Have malignancy or metastasis of the central nervous system~* Have borderline malignancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1b (Cohort 1) LY2228820 200 milligrams (mg) (Type: EXPERIMENTAL): Cohort 1: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 milligrams per square meter (mg/m\^2) administered intravenously (IV) over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3..~Cohort 1: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14.
- Phase 1b (Cohort 2) LY2228820 300 mg (Type: EXPERIMENTAL): Cohort 2: Cycles 1-6 (21 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m\^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Cohort 2: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14.
- Phase 2 (Arm A) LY2228820 200 mg (Type: EXPERIMENTAL): Arm A: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m\^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Arm A: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14.
- Phase 2 (Arm B) Placebo (Type: PLACEBO_COMPARATOR): Arm B: Cycles 1-6 (21 day cycles)- Placebo administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m\^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Arm B: Cycle 7+ (28 day cycles)- Placebo administered orally on days 1-14 to maintain blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).